Say you earn a decent salary, carry no insurance that covers GLP-1s, and watched tirzepatide cost $1,000-plus per month at a retail pharmacy for the past two years. You are not alone. Millions of people are in exactly that spot right now, and the telehealth market has responded with compounded and branded alternatives across a wide price range. Some are legitimate. Some have already received FDA warning letters. Sorting them out takes work, so here is a straight look at ten programs, ranked by overall value for cash-pay buyers.
1. HealthRX
Tirzepatide from $149 per month. That price point, combined with free overnight shipping to all 50 states, is what puts HealthRX at the top of this list for most cash-pay shoppers.
The workflow is straightforward. You complete an online health assessment, a U.S. board-certified physician reviews it within roughly 24 hours, and medication ships overnight if approved. The compounded tirzepatide comes from Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-tracked batches. Manifest holds LegitScript certification (cert 50087439), which is a verifiable third-party credential, not a self-awarded badge. Pricing is listed upfront, no hidden fees layered in at checkout.
Worth saying clearly: compounded medications are not FDA-approved products. They are prepared copies of a reference drug, legal under specific pharmacy rules, and they are not the same thing as branded Mounjaro or Zepbound. Trial data HealthRX references for tirzepatide, specifically around 21% average body weight reduction at 72 weeks from SURMOUNT-1, comes from the branded drug. Your results depend on dose, diet, and consistency.
Still, for someone who needs a verified pharmacy, a fast clinical turnaround, and a $149 starting price with no monthly membership tax on top, HealthRX is the clearest match.
2. Mochi Health
Compounded tirzepatide at roughly $199 per month. Mochi uses board-certified obesity-medicine clinicians, which is a meaningful credential difference compared to general telehealth. More monitoring touchpoints than most budget options.
3. FormBlends
FormBlends is a compounded GLP-1 telehealth provider with physician oversight and a dispensing setup through an FDA-registered 503A compounding pharmacy. What separates it from most competitors is transparency about what is actually in the vials. FormBlends publishes per-product purity testing, including HPLC purity percentages, mass-spectrometry identity confirmation, and endotoxin sterility data, with specific named numbers. That is rare in this space.
Cash pricing runs higher than HealthRX. Tirzepatide is around $349 per vial and semaglutide around $299. Shipping covers 47 states, not all 50. So why is it here? Two reasons. First, if you want to see the actual lab numbers before injecting anything, FormBlends shows them and most competitors do not. Second, FormBlends carries a broad peptide catalog, recovery, longevity, and cognitive compounds, under the same clinician model. If you want GLP-1 therapy and additional peptide protocols from a single provider, this is the only option on this list that handles both. Pay the premium for the transparency. That is the honest trade-off.
4. Henry Meds
Cash-pay compounded program, first month often in the $179-$249 range, with shipping typically landing within 24-72 hours. Lighter clinical monitoring than some others, which means lower overhead but also less hand-holding.
5. PlushCare
Membership at $19.99 per month, branded medications billed separately, same-day visits available. PlushCare leans on insurance coverage and can work a prior-auth process for branded tirzepatide. Best fit if you have insurance that might actually cover Zepbound.
6. Ro Body
First month around $39, then roughly $74-$149 per month for the platform, with medications billed separately. Ro has a dedicated prior-authorization team and takes insurance for branded GLP-1s. The membership model makes costs harder to compare apples-to-apples, but the prior-auth support is genuinely useful.
7. MEDVi
Compounded tirzepatide, first month around $179, no contracts. Simple structure. Worth a look if you want flexibility without a long commitment.
8. Found
Platform fee around $99 per month, plus medication costs. Found adds coaching alongside prescriptions. The combined cost adds up quickly, so it fits better for people who actually want the behavioral support built in.
9. Sesame
Annual membership from roughly $59 per month, medications priced separately. Sesame is more of a clinical marketplace than a dedicated weight-loss program, but it can be a low-cost entry point for a prescription visit.
10. Hims & Hers
After the March 2026 Novo Nordisk settlement, Hims & Hers moved to branded medications. Wegovy injectable runs around $299 per month through their platform, oral semaglutide around $249, and Zepbound around $399. With insurance plus a savings card, some members have reported hitting $0-$25. Higher floor than compounded options, but you are getting an FDA-approved product.
Comparison Table
| Provider | Tirzepatide Starting Price | Ships To | Pharmacy Type | Notable Feature |
| HealthRX | ~$149/mo | All 50 states | 503A named (Manifest, SC) | Free overnight shipping, LegitScript cert |
| Mochi Health | ~$199/mo | Most states | Compounded | Obesity-medicine clinicians |
| FormBlends | ~$349/vial | 47 states | 503A registered | Published purity testing, peptide catalog |
| Henry Meds | ~$179-249/mo | Most states | Compounded | Fast 24-72h shipping |
| PlushCare | Branded + $19.99 membership | Most states | Branded | Same-day visits, insurance support |
| Ro Body | Meds separate + ~$39 first mo | Most states | Branded/compounded | Prior-auth team |
| MEDVi | ~$179 first mo | Most states | Compounded | No contracts |
| Found | ~$99/mo + meds | Most states | Compounded/branded | Coaching included |
| Sesame | ~$59/mo + meds | Most states | Varies | Marketplace model |
| Hims & Hers | ~$399/mo Zepbound | Most states | Branded | Insurance + savings card path |
Frequently Asked Questions
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No. Compounded tirzepatide is prepared by a licensed 503A or 503B pharmacy and is not an FDA-approved drug. It uses the same active ingredient but is not manufactured by Eli Lilly and has not gone through the branded drug approval process. Compounding is legal under specific conditions, but the regulatory status is different.
Why do prices vary so much between providers?
Some programs charge a platform fee plus medication costs separately. Others bundle everything. Some use 503A pharmacies with more overhead, others use lower-cost operations. Always ask for the all-in monthly number before signing up.
Are these programs safe after the 2026 FDA warning letters?
The FDA sent warning letters to more than 30 telehealth and compounding firms in early 2026, mostly targeting unsupported efficacy claims and improper compounding. The letters do not mean all compounded tirzepatide is dangerous. They do mean you should verify your provider uses a named, licensed pharmacy with documented quality controls.
What happened to compounded GLP-1s after the Novo Nordisk settlement in March 2026?
The March 2026 settlement between Novo Nordisk and some telehealth companies led several platforms to shift from compounded semaglutide to branded Wegovy and Ozempic. Compounded tirzepatide from Lilly was a separate question and remained available through many providers as of mid-2026.
What should I check to confirm a compounding pharmacy is operating legally and safely?
Look for 503A or 503B status, USP-797 compliance for sterile products, and third-party credentials like LegitScript certification. A pharmacy that publishes lot tracking and purity testing data offers a higher level of accountability than one that does not name its facility at all.
*Prices and program details reflect publicly available information as of mid-2026 and can change. Compounded medications are not FDA-approved. Always consult a licensed physician before starting any GLP-1 program.*
Sources
- FDA: “FDA Updates on Compounding of Tirzepatide and Semaglutide,” FDA.gov (2025-2026 guidance pages)
- SURMOUNT-1 trial: Jastreboff et al., *New England Journal of Medicine*, 2022 (tirzepatide for obesity)
- STEP 1 trial: Wilding et al., *New England Journal of Medicine*, 2021 (semaglutide for weight management)
- LegitScript Healthcare Merchant Certification database, LegitScript.com
- Novo Nordisk press release on compounding settlements, March 2026, NovNordisk-us.com
- Eli Lilly LillyDirect orforglipron announcement, April 2026, LillyDirect.com
